Search
Nylidrin
go.drugbank.com/drugs/DB06152ApprovedWithdrawnNylidrin, also known as buphenine belongs to the category of drugs called vasodilators, which relax blood vessels and increase blood flow. Nylidrin is a peripheral vasodilator. Some studies show the evidence of improving cognitive impair...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesGarenoxacin
go.drugbank.com/drugs/DB06160ExperimentalGarenoxacin, a quinolone antibiotic, is being investigated for the treatment of gram-positive and gram-negative bacterial infections.
Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 Enzyme InhibitorsTolperisone
go.drugbank.com/drugs/DB06264InvestigationalTolperisone is an oral, centrally acting muscle relaxant. Its precise mechanism is not completely understood, though it blocks sodium and calcium channels. It possesses a high affinity for nervous system tissue, reaching highest concentr...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesLevocetirizine
go.drugbank.com/drugs/DB06282ApprovedInvestigationalLevocetirizine is a selective histamine H1 antagonist used to treat a variety of allergic symptoms. It is the R enantiomer of cetirizine. Levocetirizine has greater affinity for the histamine H1 receptor than cetirizine. Levocetirizine w...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesElacestrant
go.drugbank.com/drugs/DB06374ApprovedInvestigationalElacestrant is a non-steroidal small molecule and an estrogen receptor (ER) antagonist. In January 2023, it was approved by the FDA for the treatment of ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer. It re...
Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitorsMitemcinal
go.drugbank.com/drugs/DB06587InvestigationalMitemcinal (GM-611) is a novel erythromycin-derived prokinetic agent that acts as an agonist at the motilin receptor.
Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 InhibitorsVicriviroc
go.drugbank.com/drugs/DB06652InvestigationalVicriviroc, also known as SCH 417690 and SCH-D, is currently in clinical trials for the management of HIV-1. This pyrimidine based drug inhibits the interaction of HIV-1 with CCR5, preventing viral entry into cells. This drug was develop...
Categories: Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 SubstratesVilazodone
go.drugbank.com/drugs/DB06684ApprovedInvestigationalVilazodone is a novel compound with combined high affinity and selectivity for the 5-hydroxytryptamine (5-HT) transporter and 5-HT(1A) receptors[Label,A177622]. Vilazodone may also be associated with less sexual dysfunction and weight ga...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 InhibitorsLaquinimod
go.drugbank.com/drugs/DB06685InvestigationalLaquinimod is an immunomodulator developed by Active Biotech and produced by Teva Pharmaceutical Industries. It is currently under development in phase III trials for treatment of multiple sclerosis as an oral therapy, like fingolimod. I...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesArtemether
go.drugbank.com/drugs/DB06697ApprovedInvestigational</i> and may be used to treat infections caused by <i>P. falciparum</i> and unidentified <i>Plasmodium</i> species, including infections acquired in chloroquine-resistant areas.
Categories: Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 Substrates